二线治疗-话题@MedSci

#二线治疗#

120篇内容 | 3394人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1543947, encodeId=e0b3154394e37, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, objectTitle=NEJM：Asciminib二线治疗费城染色体阳性白血病, objectType=article, longId=184673, objectId=05d51846e3ec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=05d51846e3ec, replyNumber=0, likeNumber=60, createdTime=2019-12-14, rootId=0, userName=ms5768352621950538, userId=520213623738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=05d51846e3ec, moduleTitle=NEJM：Asciminib二线治疗费城染色体阳性白血病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=05d51846e3ec)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543946, encodeId=90d915439460f, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, objectTitle=NEJM：曲妥珠单抗Deruxtecan用于HER2阳性转移性乳腺癌的二线治疗, objectType=article, longId=184671, objectId=d1461846e154, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d1461846e154, replyNumber=0, likeNumber=72, createdTime=2019-12-14, rootId=0, userName=ms5768352621950538, userId=520213623738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d1461846e154, moduleTitle=NEJM：曲妥珠单抗Deruxtecan用于HER2阳性转移性乳腺癌的二线治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d1461846e154)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543945, encodeId=c8781543945fb, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, objectTitle=信迪利单抗联合化疗用于晚期肺鳞癌二线治疗，肿瘤持续缓解7个月以上, objectType=article, longId=181304, objectId=4eaa18130437, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4eaa18130437, replyNumber=0, likeNumber=80, createdTime=2019-10-17, rootId=0, userName=ms5768352621950538, userId=520213623738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4eaa18130437, moduleTitle=信迪利单抗联合化疗用于晚期肺鳞癌二线治疗，肿瘤持续缓解7个月以上, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4eaa18130437)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543944, encodeId=f12215439440d, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, objectTitle=Lancet Oncol：绝经后HR+/HER2-转移性乳腺癌一线或二线治疗——内分泌为基础治疗较化疗更优, objectType=article, longId=181205, objectId=bec7181205bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bec7181205bb, replyNumber=0, likeNumber=56, createdTime=2019-10-16, rootId=0, userName=ms5768352621950538, userId=520213623738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bec7181205bb, moduleTitle=Lancet Oncol：绝经后HR+/HER2-转移性乳腺癌一线或二线治疗——内分泌为基础治疗较化疗更优, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bec7181205bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543943, encodeId=3d0d1543943cc, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, objectTitle=病例：二线治疗鼻咽癌，让患者更多获益, objectType=article, longId=181039, objectId=c65f18103945, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c65f18103945, replyNumber=0, likeNumber=65, createdTime=2019-10-14, rootId=0, userName=ms5768352621950538, userId=520213623738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c65f18103945, moduleTitle=病例：二线治疗鼻咽癌，让患者更多获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c65f18103945)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543942, encodeId=b7fc1543942a0, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, objectTitle=2019 ESMO 瑞戈非尼120 mg联合紫杉醇二线治疗晚期食管胃癌，初显疗效, objectType=article, longId=180450, objectId=c1df1804504a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c1df1804504a, replyNumber=0, likeNumber=78, createdTime=2019-10-05, rootId=0, userName=ms5768352621950538, userId=520213623738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c1df1804504a, moduleTitle=2019 ESMO 瑞戈非尼120 mg联合紫杉醇二线治疗晚期食管胃癌，初显疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c1df1804504a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543941, encodeId=de4615439414f, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, objectTitle=肝癌分子靶向治疗面面观：从一线二线治疗决策到综合性全程管理, objectType=article, longId=179926, objectId=a3421e9926de, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a3421e9926de, replyNumber=0, likeNumber=49, createdTime=2019-09-25, rootId=0, userName=ms5768352621950538, userId=520213623738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a3421e9926de, moduleTitle=肝癌分子靶向治疗面面观：从一线二线治疗决策到综合性全程管理, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a3421e9926de)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543940, encodeId=bbc81543940c8, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, objectTitle=SCLC二线治疗三大药物造福小细胞肺癌患者, objectType=article, longId=175993, objectId=64a41e5993d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=64a41e5993d6, replyNumber=0, likeNumber=65, createdTime=2019-07-24, rootId=0, userName=ms5768352621950538, userId=520213623738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=64a41e5993d6, moduleTitle=SCLC二线治疗三大药物造福小细胞肺癌患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=64a41e5993d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543939, encodeId=c9181543939f1, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, objectTitle=诺华的新型口服CDK4/6靶向抗癌药Kisqali喜获NICE推荐，用作二线治疗晚期乳腺癌, objectType=article, longId=175681, objectId=3cfe1e5681e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3cfe1e5681e2, replyNumber=0, likeNumber=122, createdTime=2019-07-19, rootId=0, userName=ms5768352621950538, userId=520213623738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3cfe1e5681e2, moduleTitle=诺华的新型口服CDK4/6靶向抗癌药Kisqali喜获NICE推荐，用作二线治疗晚期乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3cfe1e5681e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543938, encodeId=df181543938be, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, objectTitle=苏格兰医药联盟积极推荐Darzalex作为多发性骨髓瘤的二线治疗方案, objectType=article, longId=175081, objectId=1ce51e50810d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1ce51e50810d, replyNumber=0, likeNumber=73, createdTime=2019-07-11, rootId=0, userName=ms5768352621950538, userId=520213623738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1ce51e50810d, moduleTitle=苏格兰医药联盟积极推荐Darzalex作为多发性骨髓瘤的二线治疗方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1ce51e50810d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543937, encodeId=17e1154393ed0, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, objectTitle=中国转移性结直肠癌患者二线治疗的系统性回顾及专家共识, objectType=article, longId=174720, objectId=43781e47207f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=43781e47207f, replyNumber=0, likeNumber=52, createdTime=2019-07-04, rootId=0, userName=ms5768352621950538, userId=520213623738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=43781e47207f, moduleTitle=中国转移性结直肠癌患者二线治疗的系统性回顾及专家共识, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=43781e47207f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543936, encodeId=7c8e1543936b7, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, objectTitle=帕博利珠单抗二线治疗肝癌虽未达统计学意义但显示临床获益, objectType=article, longId=168158, objectId=24ab168158c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=24ab168158c3, replyNumber=0, likeNumber=60, createdTime=2019-06-13, rootId=0, userName=ms5768352621950538, userId=520213623738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=24ab168158c3, moduleTitle=帕博利珠单抗二线治疗肝癌虽未达统计学意义但显示临床获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=24ab168158c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543935, encodeId=8eee1543935aa, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, objectTitle=免疫治疗作为Ⅰ级推荐用于晚期肝癌二线治疗, objectType=article, longId=166874, objectId=ee461668e46a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ee461668e46a, replyNumber=0, likeNumber=69, createdTime=2019-05-28, rootId=0, userName=ms5768352621950538, userId=520213623738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ee461668e46a, moduleTitle=免疫治疗作为Ⅰ级推荐用于晚期肝癌二线治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ee461668e46a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543934, encodeId=5e0e154393433, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, objectTitle=Lancet：左乙拉西坦二线治疗小儿惊厥性癫痫效果不优于苯妥英, objectType=article, longId=166804, objectId=d8c4166804f0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d8c4166804f0, replyNumber=0, likeNumber=72, createdTime=2019-05-27, rootId=0, userName=ms5768352621950538, userId=520213623738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d8c4166804f0, moduleTitle=Lancet：左乙拉西坦二线治疗小儿惊厥性癫痫效果不优于苯妥英, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d8c4166804f0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543933, encodeId=f0bc15439333e, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, objectTitle=FDA扩大了礼来的抗VEGFR2单抗Cyramza的适应症，用作肝癌患者的二线治疗, objectType=article, longId=165891, objectId=11a416589183, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=11a416589183, replyNumber=0, likeNumber=62, createdTime=2019-05-13, rootId=0, userName=ms5768352621950538, userId=520213623738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=11a416589183, moduleTitle=FDA扩大了礼来的抗VEGFR2单抗Cyramza的适应症，用作肝癌患者的二线治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=11a416589183)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543932, encodeId=cafe154393240, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, objectTitle=Lancet：左乙拉西推荐作为小儿惊厥性癫痫的二线治疗**, objectType=article, longId=164559, objectId=30ac164559ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=30ac164559ed, replyNumber=0, likeNumber=65, createdTime=2019-04-20, rootId=0, userName=ms5768352621950538, userId=520213623738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=30ac164559ed, moduleTitle=Lancet：左乙拉西推荐作为小儿惊厥性癫痫的二线治疗**, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=30ac164559ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543931, encodeId=c0d51543931ba, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, objectTitle=AIDS：资源受限环境下HIV成人患者接受二线治疗一年后生活质量得到大大改善, objectType=article, longId=163549, objectId=ead316354917, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ead316354917, replyNumber=0, likeNumber=71, createdTime=2019-04-05, rootId=0, userName=ms5768352621950538, userId=520213623738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ead316354917, moduleTitle=AIDS：资源受限环境下HIV成人患者接受二线治疗一年后生活质量得到大大改善, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ead316354917)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543930, encodeId=ffbd1543930da, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, objectTitle=J Rheumatol：关节内注射糖皮质激素作为儿童莱姆关节炎的二线治疗, objectType=article, longId=162219, objectId=2fc21622199a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2fc21622199a, replyNumber=0, likeNumber=65, createdTime=2019-03-14, rootId=0, userName=ms5768352621950538, userId=520213623738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2fc21622199a, moduleTitle=J Rheumatol：关节内注射糖皮质激素作为儿童莱姆关节炎的二线治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2fc21622199a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543929, encodeId=d071154392930, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, objectTitle=宋勇教授：超越化疗，阿帕替尼联合多西他赛二线治疗EGFR阴性NSCLC疗效初现, objectType=article, longId=150010, objectId=265815001074, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=265815001074, replyNumber=0, likeNumber=81, createdTime=2018-10-01, rootId=0, userName=ms5768352621950538, userId=520213623738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=265815001074, moduleTitle=宋勇教授：超越化疗，阿帕替尼联合多西他赛二线治疗EGFR阴性NSCLC疗效初现, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=265815001074)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543928, encodeId=92391543928df, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, objectTitle=Respir Med：恶性胸膜间皮瘤理想的二线治疗是…, objectType=article, longId=148871, objectId=1eec1488e1b1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1eec1488e1b1, replyNumber=0, likeNumber=76, createdTime=2018-09-16, rootId=0, userName=ms5768352621950538, userId=520213623738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1eec1488e1b1, moduleTitle=Respir Med：恶性胸膜间皮瘤理想的二线治疗是…, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1eec1488e1b1)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

二线治疗

2020-05-29

ms5768352621950538 (审核中...)

前往app查看评论内容

#二线治疗#

NEJM：Asciminib二线治疗费城染色体阳性白血病

2019-12-14

ms5768352621950538 (审核中...)

前往app查看评论内容

#二线治疗#

NEJM：曲妥珠单抗Deruxtecan用于HER2阳性转移性乳腺癌的二线治疗

2019-12-14

ms5768352621950538 (审核中...)

前往app查看评论内容

#二线治疗#

信迪利单抗联合化疗用于晚期肺鳞癌二线治疗，肿瘤持续缓解7个月以上

2019-10-17

ms5768352621950538 (审核中...)

前往app查看评论内容

#二线治疗#

Lancet Oncol：绝经后HR+/HER2-转移性乳腺癌一线或二线治疗——内分泌为基础治疗较化疗更优

2019-10-16

ms5768352621950538 (审核中...)

前往app查看评论内容

#二线治疗#

病例：二线治疗鼻咽癌，让患者更多获益

2019-10-14

ms5768352621950538 (审核中...)

前往app查看评论内容

#二线治疗#

2019 ESMO 瑞戈非尼120 mg联合紫杉醇二线治疗晚期食管胃癌，初显疗效

2019-10-05

ms5768352621950538 (审核中...)

前往app查看评论内容

#二线治疗#

肝癌分子靶向治疗面面观：从一线二线治疗决策到综合性全程管理

2019-09-25

ms5768352621950538 (审核中...)

前往app查看评论内容

#二线治疗#

SCLC二线治疗三大药物造福小细胞肺癌患者

2019-07-24

ms5768352621950538 (审核中...)

前往app查看评论内容

#二线治疗#

诺华的新型口服CDK4/6靶向抗癌药Kisqali喜获NICE推荐，用作二线治疗晚期乳腺癌

2019-07-19

ms5768352621950538 (审核中...)

前往app查看评论内容

#二线治疗#

苏格兰医药联盟积极推荐Darzalex作为多发性骨髓瘤的二线治疗方案

2019-07-11

ms5768352621950538 (审核中...)

前往app查看评论内容

#二线治疗#

中国转移性结直肠癌患者二线治疗的系统性回顾及专家共识

2019-07-04

ms5768352621950538 (审核中...)

前往app查看评论内容

#二线治疗#

帕博利珠单抗二线治疗肝癌虽未达统计学意义但显示临床获益

2019-06-13

ms5768352621950538 (审核中...)

前往app查看评论内容

#二线治疗#

免疫治疗作为Ⅰ级推荐用于晚期肝癌二线治疗

2019-05-28

ms5768352621950538 (审核中...)

前往app查看评论内容

#二线治疗#

Lancet：左乙拉西坦二线治疗小儿惊厥性癫痫效果不优于苯妥英

2019-05-27

ms5768352621950538 (审核中...)

前往app查看评论内容

#二线治疗#

FDA扩大了礼来的抗VEGFR2单抗Cyramza的适应症，用作肝癌患者的二线治疗

2019-05-13

ms5768352621950538 (审核中...)

前往app查看评论内容

#二线治疗#

Lancet：左乙拉西推荐作为小儿惊厥性癫痫的二线治疗**

2019-04-20

ms5768352621950538 (审核中...)

前往app查看评论内容

#二线治疗#

AIDS：资源受限环境下HIV成人患者接受二线治疗一年后生活质量得到大大改善

2019-04-05

ms5768352621950538 (审核中...)

前往app查看评论内容

#二线治疗#

J Rheumatol：关节内注射糖皮质激素作为儿童莱姆关节炎的二线治疗

2019-03-14

ms5768352621950538 (审核中...)

前往app查看评论内容

#二线治疗#

宋勇教授：超越化疗，阿帕替尼联合多西他赛二线治疗EGFR阴性NSCLC疗效初现

2018-10-01

ms5768352621950538 (审核中...)

前往app查看评论内容

#二线治疗#

Respir Med：恶性胸膜间皮瘤理想的二线治疗是…

2018-09-16

科室
- - 订阅+
  - 更多科室
工具
服务